CareDx is a leading precision medicine diagnostics company advancing care in transplant, specialty oncology, and cell therapy. Through our innovative portfolio of molecular diagnostics, digital health solutions, AI-powered data and analytics, and patient support services, we partner with healthcare providers, patients, and biopharma organizations to help inform clinical decision-making and improve patient outcomes.
Our Sales Representatives play a critical role in driving the adoption of NavDx®, a cutting-edge Lab Developed Test (LDT) designed for patients with HPV-driven cancers. NavDx detects and quantifies Tumor Tissue Modified Vial (TTMV®)-HPV DNA in blood, offering a non-invasive tool to monitor patients for recurrence after treatment. By enabling earlier detection of disease recurrence, NavDx helps clinicians optimize patient management and improve outcomes. In this role, you will engage a broad range of stakeholders—including medical oncologists, radiation oncologists, head and neck surgeons, and colorectal surgeons—within multidisciplinary care teams to expand clinical awareness and utilization of NavDx.
Responsibilities:
- Consistently achieve and exceed sales targets across a diverse customer base and the company’s product portfolio through effective business planning and execution.
- Drive new and existing account growth via product launches, expanded usage, and tailored marketing support.
- Educate customers on product clinical value, safety, and indications while identifying opportunities and resolving challenges proactively.
- Engage in a consultative selling process to identify customer pain points, develop account specific solutions, secure stakeholder buy-in for adopting those solutions, and supporting the implementation of those solutions to drive long-term utilization of the NavDx test in the customer’s practice.
- Manage territory efficiently (Southern California and Arizona) through strategic call planning, CRM utilization (Salesforce), and timely administrative follow-through.
- Represent the company with professionalism, integrity, and strong ethical standards and maintain strict adherence to quality and regulatory standards.
Minimum Education, Experience, & Specialized Knowledge (Required):
- 7+ year in healthcare sales, with 5+ years in a start-up environment (preferred) and 3+ years selling Laboratory Developed Tests (LDTs) to healthcare providers treating cancer (strongly preferred).
- Proven track record of exceeding sales goals in a complex sales environment and earning performance recognition.
- Experience launching new LDTs and managing large, multi-state territories independently.
- Demonstrated success in complex and strategic sales processes (e.g. capital equipment, enterprise solutions). Knowledge of complex selling methodologies (e.g. Miller Heiman) are a differentiator for candidates.
- Successful engagement with Medical Oncologists, Radiation Oncologists, Otolaryngologists, and Colorectal Surgeons.
- Strong relationships with key academic centers; experienced in complex, multi-specialty disease settings.
- Proficient in Excel, Salesforce.com, and Tableau for data analysis and strategic targeting.
- Effective communication and presentation skills with the ability to influence a paradigm change in practice patterns with various healthcare professionals, including physicians, nurses, and office staff.
- Able to travel domestically up to 75%.
- Valid U.S. driver’s license and authorization to work in the U.S. without sponsorship.
- Capable of performing all essential job duties with or without accommodation.
- Must live in Southern California.
CareDx, Inc. is an Equal Opportunity Employer-vets/disabled, and participates in the E-Verify program. By proceeding with our application and submitting your information, you acknowledge that you have read our U.S. Personnel Privacy Notice and consent to receive email communication from CareDx. Certain jurisdictions require notice of how we use and protect your personal information. For more information, please read our Privacy Policy
The U.S. EEO posters are available here.
Note: We do not accept resumes from headhunters, placement agencies, or other suppliers that have not signed a formal agreement with us.
This is the anticipated base salary range in the United States. The final salary offered to a successful candidate will be dependent on several factors that may include, but are not limited to, the type and length of experience within the job, the type and length of experience within the industry, education, etc. Base pay is one part of the Total Package that is provided to compensate and recognize employees for their work, and this role may be eligible for additional discretionary bonuses/incentives and restricted stock units. CareDx is a multi-state employer, and this salary range may not reflect positions that work in other states.
Skills Required
- 7+ years in healthcare sales
- 5+ years in a start-up environment
- 3+ years selling Laboratory Developed Tests (LDTs) to oncology providers
- Proven track record of exceeding sales goals in a complex sales environment
- Experience launching new LDTs and managing large, multi-state territories independently
- Demonstrated success in complex and strategic sales processes (e.g., capital equipment, enterprise solutions)
- Knowledge of complex selling methodologies (e.g., Miller Heiman)
- Successful engagement with Medical Oncologists, Radiation Oncologists, Otolaryngologists, and Colorectal Surgeons
- Strong relationships with key academic centers and multi-specialty disease settings experience
- Proficient in Excel, Salesforce.com, and Tableau
- Effective communication and presentation skills with ability to influence clinical practice
- Able to travel domestically up to 75%
- Valid U.S. driver's license
- Authorization to work in the U.S. without sponsorship
- Capable of performing all essential job duties with or without accommodation
- Must live in Southern California
What We Do
CareDx: Transforming Transplant Patient Care Through Novel Surveillance Management Solutions CareDx, Inc. is dedicated to improving the lives of organ transplant patients through non-invasive diagnostics. By combining the latest advances in genomics and bioinformatics technology, with a commitment to generating high quality clinical evidence through trials and registries, CareDx is at the forefront of organ transplant surveillance and pre-transplant HLA typing solutions. NASDAQ:CDNA About AlloSure® AlloSure is the first and only non-invasive blood test that directly measures allograft injury and identifies the probability of active rejection to better manage kidney transplant patients. AlloSure is a clinical-grade, proprietary Next-Generation Sequencing (NGS) based test to detect donor-derived cell-free DNA (dd-cfDNA) in order to identify organ injury in kidney transplant recipients. AlloSure is analytically validated as a sensitive, specific, and precise measurement of dd-cfDNA. AlloSure detects active rejection (acute active ABMR, chronic active ABMR, or TCMR) with high accuracy, outperforms serum creatinine in kidney transplant recipients, and is highly sensitive in distinguishing ABMR from no ABMR. AlloSure is performed in the CareDx CLIA-certified laboratory. http://www.allosure.com/ About AlloMap® AlloMap Molecular Expression Testing is a non-invasive blood test used to aid in the identification of heart transplant recipients with stable allograft function who have a low probability of moderate/severe acute cellular rejection at the time of testing in conjunction with standard clinical assessment. AlloMap testing measures the expression levels of 20 genes from a blood sample. The combined expression of these genes is represented as an AlloMap test score. AlloMap is performed in the CareDx CLIA-certified laboratory and has been commercially available in the United States since 2005. AlloMap was cleared by the U.S. Food and Drug Administration in 2008 and was CE marked for the European Union in 2011. Use of AlloMap is also included in the International Society for Heart and Lung Transplantation (ISHLT) Practice Guidelines, published in August 2010, the worldwide standard for the care of heart transplant patients. http://www.allomap.com/
